TEXT OF INTERVIEW
Jeremy Hobson: It’s hard out there for a CEO. That’s the word from insiders at Pfizer who say the company’s board was worried about how CEO Jeffrey Kindler was handling the stress of his job. Kindler sudden retirement was announced earlier this week. As for the customers of a drug company like Pfizer, well life’s about to get more stressful for them too. One major health insurer recently told consumers that prices are about to go up.
For more on this, let’s bring in LA Times consumer columnist David Lazarus. David, welcome back.
David Lazarus: Thank you.
HOBSON: So you’re experiencing this problem in a very personal way.
LAZARUS: Well I am, in the sense that UnitedHealthcare — which is my employer-provided insurer — has just raised the cost of one of the most widely prescribed insulins out there, it’s called Novolog. And as it happens, I’m a Type-1 diabetic. I’m going to see my co-pay rise 250 percent as a result of this, raising my annual insulin costs to over $800.
HOBSON: Over $800. So it’s a really big impact on your wallet.
LAZARUS: And this isn’t just about me and it’s not just about insulin, this about anyone who takes a prescription drug to manage some sort of condition and is essentially a captive of the insurance industry when they dictate terms. Because in some cases, as with insulin, there is no generic equivalent; you can’t switch to something else that will be cheaper but still have the same desired effect. So when an insurer says, it’s going to be this way or you’re going to pay a lot more out-of-pocket, well, I and anyone else who has a chronic condition is suddenly backed against a wall, not to put too fine a point on it, and held hostage by such a decision.
HOBSON: Why is this happening right now, David?
LAZARUS: It’s happening because there’s a lot of pressure to reign in medical costs. And that pressure is warranted — medical costs are soaring, it’s one of the reasons our insurance premiums are going up, and it’s one of the reasons our health care system is so out of whack. So no one really begrudges an insurer wanting to try to keep these costs down, but in the case of certain medicines, where there is no generic equivalent, it’s just simply a matter of fairness and access to the treatment that’s going to allow you to manage your condition. If there was a cheaper alternative, great — I would use it — but there isn’t. And in fact, endocrinologists say that the switch that UnitedHealthcare would like me to make could in fact affect my condition overall and perhaps exacerbate the situation.
HOBSON: Yeah as if a chronic medical condition isn’t tough enough. David Lazarus, consumer columnist for the L.A. Times, thanks again for joining us.
LAZARUS: A pleasure.
As a nonprofit news organization, our future depends on listeners like you who believe in the power of public service journalism.
Your investment in Marketplace helps us remain paywall-free and ensures everyone has access to trustworthy, unbiased news and information, regardless of their ability to pay.
Donate today — in any amount — to become a Marketplace Investor. Now more than ever, your commitment makes a difference.